MRK Merck & Co., Inc.

bullish · high conviction track record → $118.72 -1.17 (-1.0%)
Mkt Cap $293B P/E 33.4 fwd 12.4 52wk $75.40 - $125.14 24d ago
Factor divergence: DIVERGENCE: price_momentum bullish vs estimate_revisions, analyst_revisions, narrative_gap, options_
Est. revisions: -107.3%
Factor Model (net -3.0)

Factor Model

net -3.0 5.7 / 10
Est. Revisions
-1.0
Insider Activity
+0.0
Momentum
+0.5
Analyst Rev.
-1.0
Narrative Gap
-0.5

Merck Raises 2026 Profit Guidance on Keytruda Strength

Watch: Watch upcoming FDA decisions and clinical updates this summer for momentum in oncology and pipeline expansion.

Merck raised its 2026 profit guidance to $5.04-$5.16 per share and revenue to $65.8 billion-$67 billion after beating Q1 estimates. Keytruda sales surged 12% to $8 billion, surpassing the $7.6 billion forecast. Morgan Stanley lifted its price target from $109 to $112, maintaining an Equal Weight rating on May 1, 2026.

Stronger Keytruda sales and raised guidance support Merck's recovery and growth trajectory despite mixed analyst sentiment and recent share price weakness.

Evidence

8d ago Healthcare Stocks Are on Fire -- Don't Miss These Opportunities yahoo-finance
19d ago Merck (MRK) Tops Quarterly Sales Forecasts as Keytruda Drives Growth yahoo-finance
24d ago Cardinal Health (CAH) Price Target Upped by $4 After Beating Q1 Profit Estimates yahoo-finance
27d ago Do Wall Street Analysts Like Merck & Co. Stock? yahoo-finance
31d ago Merck posts quarterly loss due to Cidara charge, sales rise 5% yahoo-finance
31d ago Merck posts quarterly loss due to Cidara charge, sales rise 5% yahoo-finance
31d ago Wells Fargo main MRK: Overweight → Overweight
36d ago Jim Cramer Says “Merck Is Terrific” yahoo-finance
7 older signals
37d ago Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.
38d ago Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer
44d ago UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview
45d ago Precursor for Semiconductor Market Growth Opportunities, - openPR.com
47d ago Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?
49d ago Insider sell by ZACHARY JENNIFER L (MRK): $14,485,690
49d ago Insider buy by THULIN INGE G (MRK): $250,000
Fundamentals & Data ▾
Merck & Co., Inc. Healthcare · Drug Manufacturers - General
Mkt Cap
$293B
P/E
33.4 fwd 12.4
Beta
0.20
Div Yield
286.00%
52w Range
$75.40 - $125.14
Short Interest
29.1M 1.18%
Days to Cover
3.2 +6%
Technicals mixed
vs 20d MA
+3.5%
from 52w Hi
-3.6%
Vol (20d)
28%
1w return
+2.5%
1m return
+7.0%
Vol ratio
1.3x
Insiders
selling 0B / 4S
Analysts
mixed
EPS Estimate
$-0.15 -107.3% 30d 0up / 3dn
Est. Dispersion
223% 5 analysts
Analyst Target
$130 $100 - $150
Options P/C
0.63 3C / 2P unusual
Fund Convergence
strong D.E. Shaw, Citadel, Bridgewater
Financials
Revenue
$16.3B +5% YoY
FCF
$2.9B
Gross Margin
74%
Op Margin
-20%
Momentum: accelerating
Top Holders
D.E. Shaw $9.1B
Citadel $1.5B
Bridgewater $33M
Recent Filings & Data
insider trade 13
net selling
12 insiders · 13 transactions (30d)
Recent transactions
LITCHFIELD CAROLINE · other
LI DEAN Y · other
LARSON BETTY D · other
SMART DALTON E. III · exercise · $155,349
DAVIS ROBERT M · other
DELUCA RICHARD ROBERT JR. · other
CHATTOPADHYAY SANAT · other
GUINDO CHIRFI · exercise · $216,429
ZACHARY JENNIFER L · other
WILLIAMS DAVID MICHAEL · other
OOSTHUIZEN JOHANNES JACOBUS · other
MARALDO DAVID R. · exercise · $61,912
SMART DALTON E. III · exercise · $42,957
Track Record (0/1 correct) ▾

Direction History

0/1 correct at 5 days
2026-04-17 bullish -6.0% ✗
Full track record across all stocks →
15 signals · latest 8d ago

Keep reading the market

Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.

All stocks → Track record → How it works →